Anebulo Pharmaceuticals, Inc.
ANEB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $4 | $6 | $3 |
| G&A Expenses | $0 | $5 | $0 | $0 |
| SG&A Expenses | $5 | $5 | $6 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $8 | $12 | $7 |
| Operating Income | -$9 | -$8 | -$12 | -$7 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $0 | $0 | $0 |
| Pre-Tax Income | -$8 | -$8 | -$12 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$8 | -$12 | -$7 |
| % Margin | – | – | – | – |
| EPS | -0.25 | -0.32 | -0.47 | -0.29 |
| % Growth | 21.9% | 31.9% | -62.1% | – |
| EPS Diluted | -0.25 | -0.32 | -0.47 | -0.29 |
| Weighted Avg Shares Out | 34 | 26 | 25 | 23 |
| Weighted Avg Shares Out Dil | 34 | 26 | 25 | 23 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | -$8 | -$12 | -$7 |
| % Margin | – | – | – | – |